MEX3C

Summary

MEX3C (mex-3 RNA binding family member C, HGNC:28040) is a protein-coding gene on chromosome 18q21.2, encoding RNA-binding E3 ubiquitin-protein ligase MEX3C (Q5U5Q3). E3 ubiquitin ligase responsible for the post-transcriptional regulation of common HLA-A allotypes.

This gene encodes a member of a family of proteins with two K homology (KH) RNA-binding domains and a C-terminal RING-finger domain. The protein interacts with mRNA via the KH domains, and the protein shuttles between the nucleus and cytoplasm. Polymorphisms in this gene may contribute to hypertension.

Source: NCBI Gene 51320 — RefSeq curated summary.

At a glance

• GWAS associations: 15
• Clinical variants (ClinVar): 7 total
• MANE Select transcript: NM_016626

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28040
Approved symbol	MEX3C
Name	mex-3 RNA binding family member C
Location	18q21.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ38871, RNF194
Ensembl gene	ENSG00000176624
Ensembl biotype	protein_coding
OMIM	611005
Entrez	51320

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000406189, ENST00000591040, ENST00000592416

RefSeq mRNA: 1 — MANE Select: NM_016626 NM_016626

CCDS: CCDS11951

Canonical transcript exons

ENST00000406189 — 2 exons

Exon	Start	End
ENSE00001702326	51196567	51197681
ENSE00001918848	51174550	51177576

Expression profiles

Bgee: expression breadth ubiquitous, 282 present calls, max score 98.90.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 17.8419 / max 192.1622, expressed in 1799 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
171973	8.0391	1723
171972	4.3545	1422
171969	2.1061	1148
171974	1.7413	890
171971	0.7398	428
171970	0.7185	402
171977	0.1162	3
171976	0.0199	3
208559	0.0041	3
208558	0.0024	2

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	98.90	gold quality
secondary oocyte	CL:0000655	98.24	gold quality
left testis	UBERON:0004533	97.27	gold quality
right testis	UBERON:0004534	97.20	gold quality
testis	UBERON:0000473	95.57	gold quality
male germ cell	CL:0000015	94.63	gold quality
ventricular zone	UBERON:0003053	94.30	gold quality
ganglionic eminence	UBERON:0004023	93.96	gold quality
germinal epithelium of ovary	UBERON:0001304	93.94	gold quality
palpebral conjunctiva	UBERON:0001812	93.30	gold quality
embryo	UBERON:0000922	92.73	gold quality
mucosa of paranasal sinus	UBERON:0005030	92.68	gold quality
oocyte	CL:0000023	92.65	gold quality
choroid plexus epithelium	UBERON:0003911	92.01	gold quality
parietal pleura	UBERON:0002400	91.84	gold quality
cortical plate	UBERON:0005343	91.45	gold quality
tibia	UBERON:0000979	91.28	gold quality
pleura	UBERON:0000977	91.18	gold quality
mammary duct	UBERON:0001765	91.08	gold quality
visceral pleura	UBERON:0002401	90.92	gold quality
epithelium of mammary gland	UBERON:0003244	90.89	gold quality
adult organism	UBERON:0007023	90.88	gold quality
epithelium of nasopharynx	UBERON:0001951	90.77	gold quality
superficial temporal artery	UBERON:0001614	90.76	gold quality
amniotic fluid	UBERON:0000173	90.57	gold quality
stromal cell of endometrium	CL:0002255	90.43	gold quality
gingival epithelium	UBERON:0001949	90.38	gold quality
caput epididymis	UBERON:0004358	90.34	gold quality
esophagus squamous epithelium	UBERON:0006920	90.33	gold quality
bone marrow cell	CL:0002092	90.26	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.93

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

259 targeting MEX3C, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3162-3P	100.00	65.37	363
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-34C-5P	99.97	70.45	1577

Literature-anchored findings (GeneRIF, showing 9)

• In combination sibling-pair linkage analysis and case-control association studies of chromosome 18, RKHD2 is found to contribute to the genetic susceptibility of essential hypertension. (PMID:17015768)
• The RNA-binding E3 ubiquitin ligase MEX-3C links ubiquitination with MHC-I mRNA degradation (PMID:22863774)
• associates with cytoplasmic deadenylation complexes and ubiquitinates CNOT7 (PMID:26471122)
• Data suggest that KH1 and HK2 domains of MEX3C bind with high affinity to MRE10, a 10-mer RNA (5prime-CAGAGUUUAG-3prime) containing an eight-nucleotide MEX3C recognition element motif (AGAGUUUA); 3prime-untranslated region of HLA-A2 mRNA contains such a high affinity binding site for KH domains of MEX3C. (MEX3C = mex-3 RNA binding family member C; HLA-A2 = HLA class I histocompatibility antigen, A-2 alpha chain) (PMID:28808060)
• MEX3C promotes osteosarcoma malignant progression through negatively regulating FGF14. (PMID:32862604)
• Circ_0007841 accelerates ovarian cancer development through facilitating MEX3C expression by restraining miR-151-3p activity. (PMID:33896797)
• MEX3C-Mediated Decay of SOCS3 mRNA Promotes JAK2/STAT3 Signaling to Facilitate Metastasis in Hepatocellular Carcinoma. (PMID:36112698)
• MEX3C as a potential target for hepatocellular carcinoma drug and immunity: combined therapy with Lenvatinib. (PMID:37828435)
• Ubiquitylation of RUNX3 by RNA-binding ubiquitin ligase MEX3C promotes tumorigenesis in lung adenocarcinoma. (PMID:38424632)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
mus_musculus	Mex3c	ENSMUSG00000037253
rattus_norvegicus	Mex3c	ENSRNOG00000015777
drosophila_melanogaster	CG11360	FBGN0039920
caenorhabditis_elegans	mex-3	WBGENE00003229

Paralogs (3): MEX3D (ENSG00000181588), MEX3B (ENSG00000183496), MEX3A (ENSG00000254726)

Protein

Protein identifiers

RNA-binding E3 ubiquitin-protein ligase MEX3C — Q5U5Q3 (reviewed: Q5U5Q3)

Alternative names: RING finger and KH domain-containing protein 2, RING finger protein 194, RING-type E3 ubiquitin transferase MEX3C

All UniProt accessions (3): Q5U5Q3, A0A6Q8PG18, K7ER23

UniProt curated annotations — full annotation on UniProt →

Function. E3 ubiquitin ligase responsible for the post-transcriptional regulation of common HLA-A allotypes. Binds to the 3’ UTR of HLA-A2 mRNA, and regulates its levels by promoting mRNA decay. RNA binding is sufficient to prevent translation, but ubiquitin ligase activity is required for mRNA degradation.

Subunit / interactions. Interacts with USP7, which antagonizes the ability to degrade mRNA.

Subcellular location. Cytoplasm. Nucleus.

Tissue specificity. Highest levels found in fetal brain and testis. Also expressed in thymus, salivary gland and uterus. Highly expressed in cells of the innate immune system, in particular activated NK cells. Week expression in the intestine.

Disease relevance. Genetic variations in MEX3C may be associated with susceptibility to essential hypertension.

Domain organisation. Binds RNA through its KH domains.

RefSeq proteins (1): NP_057710* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001841	Znf_RING	Domain
IPR004087	KH_dom	Domain
IPR004088	KH_dom_type_1	Domain
IPR013083	Znf_RING/FYVE/PHD	Homologous_superfamily
IPR036612	KH_dom_type_1_sf	Homologous_superfamily
IPR047226	KH-I_MEX3_rpt2	Domain
IPR047227	MEX3	Family
IPR047228	KH-I_MEX3_rpt1	Domain

Pfam: PF00013, PF13920

Enzyme classification (BRENDA):

• EC 2.3.2.27 — RING-type E3 ubiquitin transferase (BRENDA: 28 organisms, 138 substrates, 10 inhibitors, 1 Km, 1 kcat entries)

Substrate kinetics (BRENDA)

1 substrates with measured Km, best-characterized 1. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
[UBE2W]-S-UBIQUITINYL-L-CYSTEINE	0.3014	1

UniProt features (44 total): helix 11, strand 11, compositionally biased region 7, modified residue 3, domain 2, sequence conflict 2, turn 2, region of interest 2, chain 1, sequence variant 1, mutagenesis site 1, zinc finger region 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
5WWW	X-RAY DIFFRACTION	1.8
5WWX	X-RAY DIFFRACTION	2
5ZI6	X-RAY DIFFRACTION	2.2
5WWZ	X-RAY DIFFRACTION	2.5

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5U5Q3-F1	60.36	0.28

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 88, 537, 545

Mutagenesis-validated functional residues (1):

Position	Phenotype
343	prevents rna binding.

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-983168	Antigen processing: Ubiquitination & Proteasome degradation
R-HSA-1280218	Adaptive Immune System
R-HSA-168256	Immune System
R-HSA-983169	Class I MHC mediated antigen processing & presentation

MSigDB gene sets: 240 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_UP, GOBP_REGULATION_OF_FAT_CELL_DIFFERENTIATION, GOBP_CARTILAGE_DEVELOPMENT, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, GOBP_SKELETAL_SYSTEM_DEVELOPMENT, REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION, REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION, GCM_ZNF198, GOBP_GROWTH, TATTATA_MIR374, GOBP_CHONDROCYTE_DEVELOPMENT, CATTTCA_MIR203, ONKEN_UVEAL_MELANOMA_UP, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1, AAACCAC_MIR140

GO Biological Process (3): chondrocyte hypertrophy (GO:0003415), regulation of fat cell differentiation (GO:0045598), energy homeostasis (GO:0097009)

GO Molecular Function (7): RNA binding (GO:0003723), zinc ion binding (GO:0008270), ubiquitin protein ligase activity (GO:0061630), nucleic acid binding (GO:0003676), protein binding (GO:0005515), transferase activity (GO:0016740), metal ion binding (GO:0046872)

GO Cellular Component (2): nucleus (GO:0005634), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Class I MHC mediated antigen processing & presentation	1
Immune System	1
Adaptive Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	2
chondrocyte development	1
developmental cell growth	1
fat cell differentiation	1
regulation of cell differentiation	1
multicellular organismal-level homeostasis	1
nucleic acid binding	1
transition metal ion binding	1
ubiquitin-protein transferase activity	1
ubiquitin-like protein ligase activity	1
catalytic activity	1
cation binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1148 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MEX3C	TRIM4	Q9C037	754
MEX3C	DCP1A	Q9NPI6	734
MEX3C	RNF135	Q8IUD6	699
MEX3C	TRIM25	Q14258	692
MEX3C	HNRNPK	P61978	645
MEX3C	AGO1	Q9UL18	601
MEX3C	RNF122	Q9H9V4	596
MEX3C	AGO2	Q9UKV8	560
MEX3C	PTGIS	Q16647	549
MEX3C	CYP4A11	Q02928	548
MEX3C	RNF125	Q96EQ8	546
MEX3C	ZNF516	Q92618	539
MEX3C	UBE2S	Q16763	521
MEX3C	GNB3	P16520	509
MEX3C	DHX36	Q9H2U1	503

IntAct

26 interactions, top by confidence:

A	B	Type	Score
YWHAH	PLEKHG3	psi-mi:“MI:0914”(association)	0.610
MEX3C	YWHAE	psi-mi:“MI:0915”(physical association)	0.560
PIP4K2A	AP3B1	psi-mi:“MI:0914”(association)	0.530
EPB41L1	AP3B1	psi-mi:“MI:0914”(association)	0.530
PIP	TBKBP1	psi-mi:“MI:0914”(association)	0.530
MEX3C	USP7	psi-mi:“MI:0915”(physical association)	0.520
USP7	MEX3C	psi-mi:“MI:0915”(physical association)	0.520
YWHAB	PLEKHG3	psi-mi:“MI:0914”(association)	0.480
SFN	MEX3C	psi-mi:“MI:0915”(physical association)	0.400
MEX3C	RUNX3	psi-mi:“MI:0915”(physical association)	0.400
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
NUDCD1	TUBAL3	psi-mi:“MI:0914”(association)	0.350
LMO2	APBB1	psi-mi:“MI:0914”(association)	0.350
YWHAH	FOXO6	psi-mi:“MI:0914”(association)	0.350
PIP	RBM47	psi-mi:“MI:0914”(association)	0.350
LMO2	POLR2D	psi-mi:“MI:0914”(association)	0.350
HDAC11	CCDC22	psi-mi:“MI:0914”(association)	0.350
MEX3C		psi-mi:“MI:0914”(association)	0.350
MEX3C		psi-mi:“MI:0915”(physical association)	0.000

BioGRID (113): MEX3C (Affinity Capture-MS), ADAR (Affinity Capture-MS), AIFM1 (Affinity Capture-MS), AP2A1 (Affinity Capture-MS), AP2A2 (Affinity Capture-MS), AP2B1 (Affinity Capture-MS), ATAD3A (Affinity Capture-MS), ATXN2L (Affinity Capture-MS), BMS1 (Affinity Capture-MS), MTHFD1 (Affinity Capture-MS), CAD (Affinity Capture-MS), CCAR2 (Affinity Capture-MS), CNOT1 (Affinity Capture-MS), CNOT3 (Affinity Capture-MS), DHX37 (Affinity Capture-MS)

ESM2 similar proteins: A1L020, A1L3F4, A7X8B3, A7X8B5, A7X8B7, A7X8B9, A7X8C2, A7X8C4, A7X8C7, A7X8C9, A7X8D2, A7X8D4, A7XW25, O97775, O97776, O97952, O97960, P06401, P10275, P84550, P84551, P89463, Q01JD1, Q05A36, Q0VDT2, Q3UE17, Q5PQQ7, Q5U5Q3, Q69Z36, Q6QT55, Q6ZK57, Q6ZN04, Q71FD5, Q7RTV3, Q7TSJ6, Q7XQN1, Q7XT42, Q84SL2, Q86XN8, Q8BQ89

Diamond homologs: A1E2V0, A1L020, A1L3F4, A9JTP3, A9ULZ2, O08863, O62640, Q05A36, Q0MW30, Q13489, Q13490, Q3UE17, Q5U5Q3, Q62210, Q69Z36, Q6TEM9, Q6ZN04, Q7XI08, Q86XN8, Q8JHV9, Q90660, Q9SYH3, A8MQ27, P41436, A2AWP0, A5D8Q0, D3ZDI6, E3SCZ8, F4IDI6, O10324, O15392, O70201, O81851, O88738, P40629, P41454, P98170, Q05AK5, Q0WPJ7, Q13075

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
Ub:E2	“up-regulates activity”	MEX3C	ubiquitination

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 23 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Translocation of SLC2A4 (GLUT4) to the plasma membrane	5	40.6×	5e-06
RHO GTPase Effectors	5	17.9×	1e-04
Transcriptional Regulation by TP53	5	16.3×	2e-04
Membrane Trafficking	6	11.7×	1e-04
Cell Cycle	6	11.4×	2e-04
Vesicle-mediated transport	6	11.0×	2e-04
Viral Infection Pathways	6	9.7×	3e-04
Signaling by Rho GTPases	5	9.0×	2e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

7 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	3
Likely benign	1
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

4236 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
18:51176392:A:G	C647R	1.000
18:51176399:A:C	C644W	1.000
18:51176400:C:G	C644S	1.000
18:51176400:C:T	C644Y	1.000
18:51176401:A:G	C644R	1.000
18:51176401:A:T	C644S	1.000
18:51176433:G:T	A633D	1.000
18:51176436:C:G	C632S	1.000
18:51176437:A:G	C632R	1.000
18:51176437:A:T	C632S	1.000
18:51176444:G:C	C629W	1.000
18:51176445:C:T	C629Y	1.000
18:51176446:A:G	C629R	1.000
18:51176448:A:G	F628S	1.000
18:51176464:A:G	C623R	1.000
18:51176472:A:G	L620P	1.000
18:51176498:G:C	C611W	1.000
18:51176499:C:G	C611S	1.000
18:51176499:C:T	C611Y	1.000
18:51176500:A:G	C611R	1.000
18:51176500:A:T	C611S	1.000
18:51176507:A:C	C608W	1.000
18:51176508:C:G	C608S	1.000
18:51176508:C:T	C608Y	1.000
18:51176509:A:G	C608R	1.000
18:51176509:A:T	C608S	1.000
18:51177159:A:T	I391N	1.000
18:51177162:T:G	H390P	1.000
18:51177163:G:C	H390D	1.000
18:51177171:A:C	I387R	1.000

dbSNP variants (sampled 300 via entrez): RS1000095906 (18:51198958 T>A,C), RS1000192189 (18:51198977 C>G,T), RS1000635662 (18:51192520 C>T), RS1000666929 (18:51192366 C>A,T), RS1000841503 (18:51181322 G>A), RS1000905267 (18:51181522 G>C,T), RS1000950268 (18:51174576 TTAAG>T,TTAAGTAAG), RS1001027065 (18:51187027 G>A), RS1001083149 (18:51175019 CTTTT>C,CTTT,CTTTTT), RS1001141795 (18:51179120 C>T), RS1001149081 (18:51187466 G>GT), RS1001251960 (18:51187935 ATCAAT>A), RS1001432328 (18:51194521 A>G), RS1001477922 (18:51187393 G>A), RS1001487918 (18:51186231 C>G)

Disease associations

OMIM: gene MIM:611005 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

15 associations (top):

Study	Trait	p-value
GCST001532_7	Immune response to smallpox vaccine (IL-6)	9.000000e-09
GCST001547_5	Immune response to anthrax vaccine	1.000000e-06
GCST006061_192	Atrial fibrillation	5.000000e-06
GCST006414_39	Atrial fibrillation	5.000000e-08
GCST006414_96	Atrial fibrillation	2.000000e-08
GCST006624_130	Systolic blood pressure	2.000000e-16
GCST007267_38	Systolic blood pressure	3.000000e-16
GCST007797_43	Asthma onset (childhood vs adult)	5.000000e-06
GCST007798_121	Asthma	6.000000e-08
GCST007800_99	Asthma (childhood onset)	4.000000e-13
GCST009325_63	Parkinson’s disease or first degree relation to individual with Parkinson’s disease	1.000000e-08
GCST009391_1640	Metabolite levels	5.000000e-06
GCST010241_330	Apolipoprotein A1 levels	3.000000e-08
GCST012053_3	Weight	8.000000e-07
GCST012490_210	Femur bone mineral density x serum urate levels interaction	2.000000e-09

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0004645	response to vaccine
EFO:0004873	cytokine measurement
EFO:0006335	systolic blood pressure
EFO:0004847	age at onset
EFO:0007787	plasma betaine measurement
EFO:0004614	apolipoprotein A 1 measurement
EFO:0004338	body weight
EFO:0004531	urate measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs17751934	Toxicity	3	Bisphosphonates	Osteonecrosis

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs17751934	MEX3C	3	0.00	1	Bisphosphonates

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects expression, increases expression	3
Valproic Acid	affects expression, decreases methylation	2
FR900359	increases phosphorylation	1
triphenyl phosphate	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
potassium chromate(VI)	increases expression, affects cotreatment	1
epigallocatechin gallate	affects cotreatment, increases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
K 7174	increases expression	1
abrine	increases expression	1
Sunitinib	increases expression	1
Zoledronic Acid	increases expression	1
Leflunomide	increases expression	1
Acetaminophen	increases expression	1
Allergens	affects cotreatment, increases abundance, increases expression	1
Arsenic	affects expression	1
Vehicle Emissions	affects cotreatment, increases abundance, increases expression	1
Cadmium	increases abundance, increases expression	1
Caffeine	affects phosphorylation	1
Cisplatin	increases expression	1
Hydrogen Peroxide	affects expression	1
Phenobarbital	affects expression	1
Ribonucleotides	affects binding	1
Silicon Dioxide	increases expression	1
Tobacco Smoke Pollution	increases expression	1
Urethane	increases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	1
Cyclosporine	increases expression	1
Aflatoxin B1	decreases methylation	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SY17	HAP1 MEX3C (-)	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.